00000nam 2200000za 4500 9.840166 CaOODSP 20221107151757 cr ||||||||||| 180119s2017 onc ob f000 0 eng d 978-0-660-09142-6 CaOODSP eng n-cn--- HP40-1/2017-3-1E-PDF Canadian guidelines on sexually transmitted infections [electronic resource] : treatment of N. gonorrhoeae in response to the discontinuation of spectinomycin : alternative treatment guidance statement. Treatment of N. gonorrhoeae in response to the discontinuation of spectinomycin : alternative treatment guidance statement Revised July 2017. [Ottawa] : Public Health Agency of Canada, 2017. 4 p. Issued also in French under title: Lignes directrices canadiennes sur les infections transmissibles sexuellement. Traitement des infections gonococciques par suite du retrait du marché de la spectinomycine : déclaration d’orientation pour les traitements de remplacement. Caption title. Includes bibliographical references. "The Public Health Agency of Canada (PHAC) has been informed that manufacturing of spectinomycin has been discontinued. Spectinomycin is recommended in the Canadian Guidelines on Sexually Transmitted Infections (CGSTI) as part of an alternate combination therapy for anogenital Neisseria gonorrhoeae infection, in individuals with contraindications to first-line treatment (i.e., cephalosporins given in combination with azithromycin or doxycycline). This guidance statement for alternative treatments for gonococcal infections was developed in consultation with the CGSTI Expert Working Group based on Canadian epidemiology and a rapid evidence review”--Issue, p. 1. gccst Sexually transmitted diseases gccst Medicine gccst Guidelines Public Health Agency of Canada. Lignes directrices canadiennes sur les infections transmissibles sexuellement (CaOODSP)9.840167 Canadian guidelines on sexually transmitted infections (CaOODSP)9.836313 PDF 364 KB https://publications.gc.ca/collections/collection_2018/aspc-phac/HP40-1-2017-3-1-eng.pdf 170170